Anti-drug resistance antibiotic

Abstract

The invention relates to a novel anti-drug resistance antibiotic. In hospitals, more than 70 percent of bacteria causing the infection of patients have drug resistance on at least more than one common antibiotic; the continuous spread of bacterial drug resistance is due to the evolution of the bacteria, however, the abuse of the antibiotic also makes the bacterial drug resistance stronger and stronger; the treatment failure of cephalomeningitis, encephalitis, myelitis, abscess, mammitis and prostatitis are mainly due to the fact that the antibiotic can not be in effective contact with pathogenic bacteria at the infected parts; the antibiotic can not penetrate through a blood brain barrier, a blood milk barrier and other biological barriers; most of antibiotics can be metabolized or inactivated very soon in various routes of administration; when the antibiotic is orally taken, the first-pass effects of the gastrointestinal tracts and the liver can break the chemical structure of the antibiotic, and thereby, most of antibiotic is inactivated; antibiotic injection can bring pains, and for some long-term patients, a long-term place with higher cost needs to be prepared to realize injection; and moreover, blood and the liver can make most of antibiotic inactivated before the antibiotic reaches the action site. The invention provides the novel antibiotic capable of taking effect by using a transdermal administration mode, can avoid the drug inactivation caused by the first-pass effects of the gastrointestinal digestive tracts and the liver and makes the local drug concentration at the infected parts reach the most proper level; meanwhile, the whole body administration is avoided; and since the antibiotic can penetrate through the blood milk barrier and the blood brain barrier, the meningitis, the mammitis, the prostatitis and other infections can be well treated.

Description

Technical field: [0001] The present invention relates to novel antibiotics against drug resistance. Background technique: [0002] β-lactam is a 4-membered cyclic amide, the chemical name of which is Azetidinone. Since 1896, French medical student Ernest Duchesne discovered penicillin, and Alexander Fleming rediscovered penicillin in 1929. In the late 1930s and early 1940s, Florey, Chain, Abraham and Heatley developed a method for purifying penicillin. Hundreds of thousands of β -Lactam antibiotics have been prepared by semi-synthetic or total synthetic methods [0003] During World War II, penicillin became a medical miracle, widely used and quickly conquering the greatest wartime killer—infected wounds. Penicillin kills many types of disease-causing bacteria. However, only four years after mass production of penicillin began in 1943, microbes resistant to penicillin began to appear, and penicillin-resistant bacteria spread rapidly. According to survey data from the US ...

AI Technical Summary

Problems solved by technology

Watts et al. (U.S. Pat. Nos. 6,191,143 and 5,929,086) proposed that some antibiotics with special structures (containing a positive charge and a lipophilic moiety) can be administered transdermally, but for most antibiotics, the transdermal The method of administration does not allow the drug to reach the concentration that can effectively treat the disease

Images